Strategic Partnerships ChromaTan’s integration with Landmark Bio and ongoing collaboration efforts present a clear sales angle to offer complementary process development, CMC, and GMP manufacturing support services, as well as potential co-development or joint commercialization opportunities around their BioRMB and Kascade platforms.

Funding Signals Recent NIH Phase IIb grant funding and ongoing investor interest (Zoic Capital) indicate momentum and credibility, suggesting a favorable environment for expanding discussions on pilot programs, grant-supported deployments, or contract research collaborations to validate the platform in real-world settings.

Tech Adoption A columnless, continuous chromatography approach positions ChromaTan as a disruptive purification solution; selling points to potential customers include reduced resin consumption, lower downtime, and scalable, cost-effective manufacturing for biologics, vaccines, and gene therapy products.

Market Entry With a focus on biopharmaceutical manufacturers seeking affordable therapies, target mid-to-large scale biotech and contract manufacturing organizations that prioritize faster development cycles and flexible single-use systems to accelerate clinical to commercial transitions.

Growth Opportunities Active participation in virtual ChromaChats roundtables demonstrates emphasis on community and knowledge exchange; this can be leveraged to identify customer pain points, qualify leads, and position ChromaTan’s platform as a collaborative solution for continuous purification challenges.